a(CHEBI:bexarotene) decreases a(HBP:HBP00018)

View Subject View Object

PubMed:21718217

Bexarotene is a highly specific RXR agonist and is currently FDA approved with a favorable side effect profile. Studies in our laboratory have shown that treatment of APP/ PS1 animals with bexarotene for only 3 days results in a dramatic induction of ApoE and ABCA1 and the rapid reversal of AD-associated pathological hallmarks including reduction in amyloid deposition and deficits in behavior as well as neural networks.

Related Edges 4

• a(CHEBI:bexarotene) increases act(p(FPLX:RXR))
• a(CHEBI:bexarotene) increases p(HGNC:APOE)
• a(CHEBI:bexarotene) increases p(HGNC:ABCA1)
• a(CHEBI:bexarotene) increases bp(GO:behavior)

Confidence

High

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---